Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHA:603139)
China · Delayed Price · Currency is CNY 38.96
-0.04 (-0.10%)
Sep 10, 2026, 3:00 PM CST
SHA:603139 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,895 | 2,045 | 1,434 | 1,875 | 1,773 | 2,174 | |
Market Cap Growth | 62.98% | 42.55% | -23.49% | 5.75% | -18.47% | 29.74% |
Enterprise Value | 4,203 | 2,654 | 2,067 | 2,467 | 2,149 | 2,371 |
Last Close Price | 39.00 | 20.47 | 14.36 | 18.77 | 17.75 | 21.69 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 59.60 |
Forward PE | - | 23.05 | 23.05 | 23.05 | 23.05 | 23.05 |
PS Ratio | 9.08 | 4.34 | 2.55 | 2.79 | 3.61 | 4.91 |
PB Ratio | 6.34 | 3.59 | 1.58 | 1.84 | 1.73 | 1.95 |
P/TBV Ratio | 8.80 | 4.74 | 1.94 | 2.26 | 2.10 | 2.40 |
P/OCF Ratio | 366.14 | - | 38.46 | - | 35.15 | 293.09 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.80 | 5.63 | 3.68 | 3.67 | 4.37 | 5.36 |
EV/EBITDA Ratio | - | - | - | 64.58 | 125.09 | 68.44 |
EV/EBIT Ratio | - | - | - | 1797.74 | - | 129.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.47 | 1.23 | 0.70 | 0.66 | 0.53 | 0.44 |
Debt / EBITDA Ratio | - | - | - | 17.18 | 31.66 | 14.30 |
Net Debt / Equity Ratio | 0.37 | 1.03 | 0.59 | 0.50 | 0.31 | 0.15 |
Net Debt / EBITDA Ratio | -4.59 | -8.38 | -258.11 | 13.21 | 18.23 | 4.96 |
Net Debt / FCF Ratio | -1.96 | -18.26 | -57.00 | -3.49 | -3.57 | -0.61 |
Asset Turnover | 0.22 | 0.26 | 0.28 | 0.35 | 0.27 | 0.28 |
Inventory Turnover | 1.31 | 2.13 | 2.06 | 3.04 | 2.50 | 2.23 |
Quick Ratio | 0.24 | 0.40 | 0.57 | 0.63 | 1.18 | 1.62 |
Current Ratio | 0.59 | 0.63 | 1.00 | 1.00 | 1.61 | 2.09 |
Return on Equity (ROE) | -37.43% | -45.58% | -11.63% | -4.96% | -7.17% | 3.02% |
Return on Assets (ROA) | -3.77% | -4.57% | -1.93% | 0.04% | -0.28% | 0.72% |
Return on Invested Capital (ROIC) | -11.85% | -10.42% | -4.11% | 0.10% | -0.62% | 1.43% |
Return on Capital Employed (ROCE) | -14.40% | -15.30% | -4.70% | 0.10% | -0.60% | 1.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -7.29% | -16.31% | -6.25% | -1.40% | -3.56% | 1.68% |
FCF Yield | -3.00% | -1.58% | -0.65% | -7.71% | -4.95% | -13.01% |
Dividend Yield | - | - | - | - | - | 0.34% |
Payout Ratio | - | - | - | - | - | 91.51% |
Buyback Yield / Dilution | 1.38% | -0.25% | 1.02% | -0.52% | -1.51% | 1.73% |
Total Shareholder Return | 1.38% | -0.25% | 1.02% | -0.52% | -1.51% | 2.07% |